Chemical debridement of burns.
The development of effective, non-toxic (local and systemic) methods for the rapid chemical (enzymatic and non-enzymatic) debridement of third degree burns would dramatically reduce the morbidity and mortality of severely burned patients. Sepsis is still the major cause of death of patients with extensive deep burns. The removal of the devitalized tissue, without damage to unburned skin or skin only partially injured by burning, and in ways which would permit immediate (or very prompt) skin grafting, would lessen substantially the problems of sepsis, speed convalescence and the return of these individuals to society as effective human beings, and would decrease deaths. The usefulness and limitations of surgical excision for patients with extensive third degree burns are discussed. Chemical debridement lends itself to complementary use with surgical excision and has the potential advantage over surgical excision in not requiring anesthesia or a formal surgical operation. The authors' work with the chemical debridement of burns, in particular the use of Bromelain, indicates that this approach will likely achieve clinical usefulness. The experimental studies indicate that rapid controlled debridement, with minimal local and systemic toxicity, is possible, and that effective chemotherapeutic agents may be combined with the Bromelain without either interfering with the actions of the other. The authors believe that rapid (hours) debridement accomplished by the combined use of chemical debriding and chemotherapeutic agents will obviate the possibility of any increase in infection, caused by the use of chemical agents for debridement, as reported for Paraenzyme(21) and Travase.(39,48) It is possible that the short term use of systemic antibiotics begun just before and continued during, and for a short time after, the rapid chemical debridement may prove useful for the prevention of infection, as appears to be the case for abdominal operations of the clean-contaminated and contaminated types.
D000818:Animals; D001963:Bromelains / Q000627:therapeutic use* / Q000633:toxicity; D002056:Burns / Q000628:therapy*; D003646:Debridement; D004285:Dogs; D005260:Female; D006400:Hematocrit; D008297:Male; D051381:Rats; D016038:Skin Transplantation; D013242:Sterilization; D013411:Sulfadiazine / Q000627:therapeutic use; D013552:Swine; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014945:Wound Healing / Q000187:drug effects; D014946:Wound Infection / Q000517:prevention & control
D013411:Sulfadiazine; D001963:Bromelains